The combination of TMZ (standard maintenance chemotherapeutic in GBM) and IR (CATNON Trial) prolonged survival only in patients with IDH-mutant astrocytoma WHO grade 3 and not in those with GBM [43]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).